Dr Lucia Nappi speaks to ecancer at ASCO 2026 about findings from the S1823/GCC.1 study, a trial evaluating circulating miR371 as a biomarker for relapse in patients with early-stage germ cell tumours managed with active surveillance.

She reports that miR371 demonstrated high specificity and negative predictive value for detecting tumour recurrence.

Dr Nappi explains that sensitivity appeared to increase with more advanced stage at relapse, suggesting miR371 may be especially useful for identifying clinically significant recurrence.